SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses
© 2022. The Author(s)..
Tumor-associated macrophages (TAMs) are one of the main cellular components in the tumor microenvironment (TME). In many types of solid tumors, TAMs tend to accumulate in hypoxic areas and are intimately related to poor patient prognosis. However, the underlying mechanisms by which TAMs infiltrate hypoxic tumor regions remain unclear. In this study, we report that genetic deletion of SE translocation (SET) in myeloid cells inhibited the entry of TAMs into the hypoxic tumor region and abated their proangiogenic and immunosuppressive functions, ultimately inhibiting tumor growth. Mechanistically, in response to hypoxic tumor supernatant stimulation, SET in macrophages shuttled between the nucleus and cytoplasm via the PKC-CK2α signaling axis. Cytoplasmic retention of SET increased ERK and P38 signaling by inhibiting PP2A, which promoted TAM migration into the hypoxic area and polarization toward the M2 phenotype. Therefore, we conclude that SET modulates tumor immunity by acting as a key regulator of macrophage positioning and function in the tumor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Experimental & molecular medicine - 54(2022), 10 vom: 12. Okt., Seite 1741-1755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Shaolong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.11.2022 Date Revised 09.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s12276-022-00867-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347394728 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347394728 | ||
| 003 | DE-627 | ||
| 005 | 20231226033720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s12276-022-00867-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347394728 | ||
| 035 | |a (NLM)36224346 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Shaolong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2022 | ||
| 500 | |a Date Revised 09.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Tumor-associated macrophages (TAMs) are one of the main cellular components in the tumor microenvironment (TME). In many types of solid tumors, TAMs tend to accumulate in hypoxic areas and are intimately related to poor patient prognosis. However, the underlying mechanisms by which TAMs infiltrate hypoxic tumor regions remain unclear. In this study, we report that genetic deletion of SE translocation (SET) in myeloid cells inhibited the entry of TAMs into the hypoxic tumor region and abated their proangiogenic and immunosuppressive functions, ultimately inhibiting tumor growth. Mechanistically, in response to hypoxic tumor supernatant stimulation, SET in macrophages shuttled between the nucleus and cytoplasm via the PKC-CK2α signaling axis. Cytoplasmic retention of SET increased ERK and P38 signaling by inhibiting PP2A, which promoted TAM migration into the hypoxic area and polarization toward the M2 phenotype. Therefore, we conclude that SET modulates tumor immunity by acting as a key regulator of macrophage positioning and function in the tumor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Zhou, Jingping |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Pengzhao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Guomeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Anlei |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Jinlei |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Yuhang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ziyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuehao |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Changying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental & molecular medicine |d 1998 |g 54(2022), 10 vom: 12. Okt., Seite 1741-1755 |w (DE-627)NLM09548373X |x 2092-6413 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:10 |g day:12 |g month:10 |g pages:1741-1755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s12276-022-00867-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 10 |b 12 |c 10 |h 1741-1755 | ||